Talis Biomedical (NASDAQ:TLIS) Stock Price Down 4.8% – Should You Sell?

Talis Biomedical Co. (NASDAQ:TLIS) fell 4.8% on Friday . The company traded as low as $1.60 and last traded at $1.60. 33,850 shares traded hands during trading, an increase of 854% from the average session volume of 3,548 shares. The stock had previously closed at $1.68.

Talis Biomedical Stock Performance

The firm has a 50 day moving average price of $1.71 and a two-hundred day moving average price of $1.91. The company has a market capitalization of $2.92 million, a P/E ratio of -0.06 and a beta of 1.52.

Institutional Trading of Talis Biomedical

An institutional investor recently raised its position in Talis Biomedical stock. BML Capital Management LLC grew its position in Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 248,702 shares of the company’s stock after purchasing an additional 205,959 shares during the period. Talis Biomedical comprises approximately 0.3% of BML Capital Management LLC’s holdings, making the stock its 24th biggest holding. BML Capital Management LLC owned about 13.66% of Talis Biomedical worth $460,000 as of its most recent filing with the SEC. 43.77% of the stock is owned by hedge funds and other institutional investors.

About Talis Biomedical

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.